Invest
27 Years
4.4 Star
1 Crore +
Pharmaceuticals company Morepen Laboratories announced Q4FY24 & FY24 results:
- Q4FY24 Revenue: Gross revenue of Rs 427 crore, 16.5% increase from Rs 367 crore in Q4’FY23.
- Annual FY24 Revenue: Rs 1,704 crore, a notable 20% rise compared to Rs 1,424 crore in FY23.
- EBITDA: EBITDA for Q4FY24 surged by 182% to Rs 52.62 crore from Rs 18.68 crore in the same quarter last year. For the full fiscal year, EBITDA more than doubled, achieving Rs 172.60 crore, up 101% from Rs 85.67 crore in FY23.
- Profit Before Tax (PBT): PBT for Q4FY24 was Rs 42.20 crore, a substantial increase of 279% from Rs 11.14 crore in Q4FY23. Annually, PBT grew by 143% to Rs 135.42 crore from Rs 55.76 crore in FY23.
- Profit After Tax (PAT): The PAT for Q4FY24 stood at Rs 28.74 crore, showing a 249% growth compared to Rs 8.24 crore in the same period last year. On an annual basis, PAT increased by 150% to Rs 96.62 crore from Rs 38.68 crore in FY23.
- Earnings Per Share (EPS): Jumped from Rs 0.77 to Rs 1.88 for FY24, indicating a great start to the journey ahead.
Sushil Suri, Chairman and Managing Director of Morepen Laboratories, commented on the results, stating, "We are excited with the robust performance across all segments. Our strategic investments in the medical devices and API businesses have yielded excellent results, and we are confident of sustaining this momentum. The future looks promising as we continue to increase capacities and expand our market reach."
FAQ’s on Morepen Laboratories Ltd Shares
